Biotech Stocks At 52-Week Highs - AMRX, BLSM, NEOG. NEO
Amneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.
How this was made
The 30-second read
Why it matters
Collective upside suggests a short‑term sector rally, but individual risks remain.
Market read
Each company's fresh catalyst drives its stock to new highs, indicating immediate trading opportunities.
What to watch
Potential pricing pressure on generic Lanreotide and execution risk on BlossomHill's later‑stage trials.
Background
The article aggregates recent positive catalysts across four biotech companies, each reaching a 52‑week high.
Ticker impact
FDA approved Amneal's generic Lanreotide injection, driving a 7% price rise to a 52‑week high.
Potential further upside as market digests approval.
Approval removes regulatory risk and supports revenue growth.
BlossomHill's Phase 1/2 data showed 88% disease control in NSCLC, lifting the stock 6% to a 52‑week high.
Continued rally expected pending further trial milestones.
High disease‑control rate is material for a clinical‑stage biotech.
Neogen reported Q4 revenue of $225 M and announced a sale of its global genomics business to Zoetis, pushing the stock 2% higher.
Modest upside as cash from the sale supports balance sheet.
Both earnings beat and asset sale are favorable catalysts.
NeoGenomics secured Medicare/Medicaid coverage for its RaDaR ST test and posted a profit, sending the share to a 52‑week high.
Potential further gains as test adoption rises.
Reimbursement approval is a key driver for diagnostic firms.
Market effects
Biotech sector gains from multiple positive regulatory and trial updates.
U.S. biotech equities see broad uplift.
Highlights continued pipeline momentum in the global pharma space.
Counterpoint
Some investors may wait for longer‑term data before adding exposure.
Key entities
- companyAmneal Pharmaceuticals
Generic drug maker receiving FDA approval.
- companyBlossomHill Therapeutics
Clinical‑stage biotech with promising NSCLC data.
- companyNeogen Corporation
Food safety solutions provider reporting earnings and divestiture.
- companyNeoGenomics
Diagnostics firm gaining payer coverage.
